Skip to main content Accessibility help
×
Home

Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic

  • P. HARDELID (a1) (a2), G. RAIT (a3), R. GILBERT (a1) and I. PETERSEN (a2) (a4)

Summary

We determined prescribing rates of neuraminidase inhibitors (NIs) for influenza in UK primary care since 2009 in relation to national prescribing guidelines. All NI prescriptions issued during the influenza seasons between October 2010 and May 2013 were extracted from The Health Improvement Network (THIN), a large UK primary-care database. We calculated NI prescribing rates per 100 000 person-weeks (pw) by age group, sex, deprivation level, influenza season and presence of chronic conditions with 95% confidence intervals (CIs), and used negative binomial regression models to determine the independent association between these variables and NI prescribing. NI prescribing was rare. The prescribing rate was 1·7/100 000 pw (95% CI 1·7–1·8) during influenza-active periods, and 0·1/100 000 (95% CI 0·1–0·1) during non-active periods. Prescribing rates were highest in 25- to 44-year-olds in 2010/2011 and in persons aged ⩾85 years in 2011/2012 and 2012/2013. Individuals with chronic conditions had significantly higher prescribing rates than persons without (rate ratio 2·62, 95% CI 2·27–3·03). GPs are more likely to prescribe NIs to high-risk individuals and during influenza active periods, as per national guidelines. We could not assess the proportion of patients with influenza-like illness who were prescribed an NI.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic
      Available formats
      ×

Copyright

Corresponding author

* Author for correspondence: Dr P. Hardelid, Population, Policy and Practice Programme, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. (Email: p.hardelid@ucl.ac.uk)

References

Hide All
1. National Institute of Health and Clinical Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza, 2009 (http://www.nice.org.uk/nicemedia/pdf/TA168fullguidance.pdf). Accessed 6 September 2012.
2. House of Commons Public Accounts Committee. Access to clinical trial information and the stockpiling of Tamiflu, 2013 (http://www.publications.parliament.uk/pa/cm201314/cmselect/cmpubacc/295/29502.htm). Accessed 22 July 2014.
3. Jefferson, T, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2014; 4: CD008965.
4. CSD Medical Research. The Health Improvement Network, 2014 (http://csdmruk.cegedim.com/our-data/our-data.shtml). Accessed: 16 April 2014.
5. Benson, T. The history of the Read codes: the inaugural James Read Memorial Lecture 2011. Informatics in Primary Care 2011;19:173182.
6. Joint Formulary Committee. British National Formulary 66. London: BMJ Group, 2014.
7. Horsfall, L, Walters, K, Petersen, I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiology and Drug Safety 2013; 22: 6469.
8. Maguire, A, Blak, BT, Thompson, M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiology and Drug Safety 2009; 18: 7683.
9. Public Health England. Surveillance of influenza and other respiratory viruses, including novel respiratory viruses, in the United Kingdom: winter 2012/2013. 2013 (http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139321787). Accessed 25 Ocober 2013
10. NHS Central Alerting System. Influenza season 2013/14 – use of antiviral medicines, 2013 (https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102108). Accessed 29 October 2014.
11. PRIMIS. Specification document for the Seasonal Influenza Immunisation Vaccine Uptake Monitoring Programme 2013/14. 2013 (http://www.primis.nottingham.ac.uk/index.php/news/hot-news/849). Accessed 9 January 2014.
12. Health and Social Care Information Centre. Quality and Outcomes Framework – 2012–13. 2013 (http://www.hscic.gov.uk/catalogue/PUB12262). Accessed 10 October 2014
13. StataCorp. Stata Statistical Software: release 13. College Station, TX: StataCorp LP, 2013.

Keywords

Type Description Title
WORD
Supplementary materials

Hardelid supplementary material S1
Hardelid supplementary material

 Word (17 KB)
17 KB

Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic

  • P. HARDELID (a1) (a2), G. RAIT (a3), R. GILBERT (a1) and I. PETERSEN (a2) (a4)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed